<DOC>
	<DOCNO>NCT00527826</DOCNO>
	<brief_summary>This 12 month randomize , open-label , parallel-group study obtain data frequency variability exacerbation severe severe Chronic Obstructive Pulmonary Disease ( COPD ) patient ( Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Stage III IV ) receive salmeterol xinafoate fluticasone propionate either fix combination ( SFC ) separate inhaler ( Sal/FP ) standard therapy . 200 subject enrol approximately 30 study centre Germany . Data health care utilisation collect compare direct cost associate COPD two group . Baseline data collect subject Visit 1 eligible subject randomize receive either SFC 50/500 µg bid ( twice daily ) fix combination Sal 50 µg bid ( twice daily ) FP 500 µg bid ( twice daily ) concurrently 52 week . Subjects return study visit every two three month week 52 . Additional telephone call make schedule visit every 4 week . Assessments include monitoring frequency exacerbation , health care utilisation ( include emergency visit hospitalization ) rescue medication , lung function , drug compliance , health-related quality life ( SGRQ = St George 's Respiratory Questionnaire ) safety .</brief_summary>
	<brief_title>Influence Of Salmeterol Xinafoate/Fluticasone Propionate ( 50/500 µg BID ) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV</brief_title>
	<detailed_description>A 12 month open-label randomized parallel group study investigate influence salmeterol xinafoate/fluticasone propionate either fix combination ( SFC50/500 µg bid ) separately ( SAL 50 µg FP 500 µg bid ) via Diskus inhaler course disease frequency exacerbation subject severe severe COPD ( GOLD stage III+IV )</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Subject must diagnosis COPD base American Thoracic Society ( ATS ) / European Respiratory Society ( ERS ) criterion . Male female subject , age &gt; =40 year . Females must Non Child Bearing Potential . The definition Non Child Bearing Potential following : Females , regardless age , function ovary current document tubal ligation hysterectomy , females postmenopausal . Have diagnose COPD stage III IV accord GOLD criterion : baseline postbronchodilator Forced Expiratory Volume , measure 1 second ( FEV1 ) &lt; 50 % predict normal baseline post bronchodilator FEV1/Inspiratory Vital Capacity ( IVC ) ratio &lt; 70 % . Have experience least 2 moderate severe COPD exacerbation lead medical consultation ( require oral corticosteroid increase dosage oral corticosteroid and/or antibiotic hospitalization ) within 12 month precede Visit 1 . Have stable COPD medication within 4 week prior Visit 1 ( new medication add dosage change medication ) . Current exsmokers smoke history least 10 pack year ( number pack year = [ number cigarette per day / 20 ] x number year smoke , e.g. , 20 cigarette per day 10 year , 10 cigarette per day 20 year ) . Are currently manage home ( outpatient ) , ambulatory able travel clinic . Subjects treat relevant COPD medication . This include vaccine , inhale shortacting beta2agonists need , shortacting longacting anticholinergic ( tiotropium ) , systemic beta2agonists , theophylline , mucolytics , antioxidant , beta1agonists ( cardiovascular indication ) , noninvasive ventilation , long term oxygen therapy Cor Pulmonale . A sign date write informed consent obtain prior participation . Able comply requirement protocol available study visit 52 week . Exclusion criterion : Known respiratory disorder sign respiratory disorder ( e.g . asthma , lung cancer , sarcoidosis , tuberculosis , lung fibrosis , cystic fibrosis , bronchoectasis ) . Known history significant inflammatory disease , COPD ( e.g . rheumatoid arthritis systemic lupus erythematosus ) . Known severely alpha1antitrypsin deficient ( PI SZ ZZ ) Having undergone lung surgery ( e.g . lung resection include lung volume reduction surgery , lung transplant ) subject schedule surgery . Concurrent medication Visit 1 duration study prohibit medication : monoamine oxidase inhibitor tricyclic antidepressant , ritonavir ( highly potent cytochrome P450 3A4 inhibitor ) . Subjects receive chronic prophylactic antibiotic therapy . Serious , uncontrolled disease ( include serious psychological disorder ) likely interfere study impact subject safety . Have , opinion investigator , evidence alcohol , drug solvent abuse . History depression . History presence clinically significant drug sensitivity clinically significant allergic reaction corticosteroid salmeterol . Moderate severe COPD exacerbation ( require corticosteroid increase dosage corticosteroid and/or antibiotic hospitalization ) within 4 week prior Visit 1 Lower respiratory tract infection within 4 week prior Visit 1 . Pregnant lactate female female childbearing potential . Subject participate investigator , subinvestigator , study coordinator , employee participate investigator , immediate family member mention . Subject employee GlaxoSmithKline ( GSK ) . Subject participate investigational drug study within 30 day prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Severe severe COPD ( GOLD stage III / IV ) exacerbation</keyword>
	<keyword>health care utilisation</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>quality life</keyword>
	<keyword>compliance</keyword>
	<keyword>salmeterol/fluticasone combination</keyword>
</DOC>